{"id":"a-c-meningococcal-polysaccharide-vaccine","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain or erythema"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Myalgia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains purified polysaccharide capsules from Neisseria meningitidis serogroups A and C, which are conjugated or presented to trigger both humoral and cellular immune responses. Upon vaccination, the immune system recognizes these antigens and generates specific antibodies and memory B cells that can rapidly respond to natural infection, preventing invasive meningococcal disease including meningitis and septicemia.","oneSentence":"This vaccine stimulates the immune system to produce antibodies against meningococcal serogroups A and C polysaccharide antigens, providing protection against meningococcal disease.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:58:25.558Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of meningococcal disease caused by Neisseria meningitidis serogroups A and C"}]},"trialDetails":[{"nctId":"NCT05935176","phase":"PHASE4","title":"Phase IV Clinical Study of Immunogenicity of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector)","status":"ACTIVE_NOT_RECRUITING","sponsor":"CanSino Biologics Inc.","startDate":"2023-09-20","conditions":"Epidemic Meningitis","enrollment":660},{"nctId":"NCT07286370","phase":"PHASE2","title":"A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella Disease and Typhoid Fever in Infants","status":"NOT_YET_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2026-02-16","conditions":"Salmonella Infections","enrollment":537},{"nctId":"NCT05794230","phase":"PHASE3","title":"Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2023-03-27","conditions":"Meningococcal Immunisation, Healthy Volunteers","enrollment":1528},{"nctId":"NCT06834100","phase":"PHASE3","title":"Assessment of Immunogenicity, Reactogenicity and Safety of the Drug GNG-DE in Comparison With the Reference Drug","status":"RECRUITING","sponsor":"NPO Petrovax","startDate":"2025-02-12","conditions":"Infections, Meningococcal","enrollment":240},{"nctId":"NCT07197762","phase":"PHASE4","title":"MenB-FHbp or MenACWY-TT/MenB-FHbp Vaccine in MenB-4C Primed Young Adults","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-11-04","conditions":"Neisseria Meningitidis","enrollment":125},{"nctId":"NCT05073003","phase":"PHASE1","title":"A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-10-06","conditions":"Diarrhoea","enrollment":551},{"nctId":"NCT04843111","phase":"","title":"Observational, Passive Surveillance Program to Collect Information on Women and Their Offspring Exposed to MenQuadfi® During Pregnancy, in United States (US)","status":"RECRUITING","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2021-03-05","conditions":"Meningococcal Infection","enrollment":50},{"nctId":"NCT05480800","phase":"PHASE1, PHASE2","title":"A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella and Typhoid Fever","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-09-13","conditions":"Salmonella Infections","enrollment":155},{"nctId":"NCT04825223","phase":"PHASE1","title":"Study of a Novel Multicomponent Meningococcal Group B Vaccine When Given Alone or With Other Licensed Vaccines in Adults, Adolescents, Toddlers and Infants","status":"TERMINATED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2021-03-29","conditions":"Meningococcal Immunisation, Healthy Volunteers","enrollment":576},{"nctId":"NCT06228586","phase":"PHASE3","title":"Study on a MenACYW Conjugate Vaccine Administered as a Single Dose in Participants Aged 12 Months and Older in Vietnam","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-01-18","conditions":"Meningococcal Infection, Healthy Volunteers","enrollment":447},{"nctId":"NCT04368429","phase":"PHASE3","title":"Study of a Quadrivalent Meningococcal Conjugate Vaccine as a Single Dose Compared With a Single Dose of a Meningococcal Reference Vaccine in Children, Adolescents, and Adults 2 to 55 Years of Age","status":"COMPLETED","sponsor":"Sanofi","startDate":"2020-05-22","conditions":"Meningococcal Immunisation (Healthy Volunteers)","enrollment":360},{"nctId":"NCT04084769","phase":"PHASE3","title":"Study to Evaluate the Immune Response After a Booster Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine When Administered Alone or Concomitantly With a Licensed Meningococcal Serogroup B Vaccine, in Participants Who Received Primary Quadrivalent Meningococcal Conjugate Vaccine (MCV4)","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2019-09-03","conditions":"Meningococcal Immunisation (Healthy Volunteers)","enrollment":570},{"nctId":"NCT03890367","phase":"PHASE3","title":"Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to Two Meningococcal Reference Vaccines in European Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2019-09-12","conditions":"Meningococcal Immunisation (Healthy Volunteers)","enrollment":707},{"nctId":"NCT04490018","phase":"PHASE3","title":"Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to a Meningococcal Reference Vaccine, and When Given Alone or With Two Other Vaccines in Healthy Adolescents","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2021-03-16","conditions":"Meningococcal Immunisation, Healthy Volunteers","enrollment":463},{"nctId":"NCT04142242","phase":"PHASE3","title":"Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine in Older Adults Who Received a Primary Vaccination (3 or More Years Earlier) in Study MET49","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2019-10-04","conditions":"Meningococcal Infection (Healthy Volunteers)","enrollment":471},{"nctId":"NCT04936685","phase":"PHASE3","title":"Study on an Investigational Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Administered as a 5- and/or 10-year Booster Doses in Children and Adolescents Vaccinated 5 or 10 Years Earlier as Toddlers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2022-08-23","conditions":"Meningococcal Immunisation, Healthy Volunteers","enrollment":209},{"nctId":"NCT05093829","phase":"PHASE3","title":"Meningococcal Serogroup ACYWX Conjugate Vaccine in Comparison With MenACWY-TT Conjugate Vaccine","status":"COMPLETED","sponsor":"Emory University","startDate":"2022-03-24","conditions":"Meningitis","enrollment":1325},{"nctId":"NCT06131554","phase":"PHASE3","title":"A Clinical Trial to Evaluate the Immunogenicity and Safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in Adults Aged 18 to 55 Years","status":"ACTIVE_NOT_RECRUITING","sponsor":"CanSino Biologics Inc.","startDate":"2024-03-20","conditions":"Meningococcal Meningitis","enrollment":1480},{"nctId":"NCT03869866","phase":"PHASE3","title":"Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) in Older Adults in Turkey and Lebanon","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2019-04-09","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":290},{"nctId":"NCT03932682","phase":"PHASE3","title":"Efficacy Study With QIVc in Pediatric Subjects","status":"COMPLETED","sponsor":"Seqirus","startDate":"2019-05-13","conditions":"Influenza, Human","enrollment":5723},{"nctId":"NCT03547271","phase":"PHASE3","title":"Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-12-14","conditions":"Meningococcal Infections","enrollment":1660},{"nctId":"NCT04143061","phase":"PHASE3","title":"Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adults, Adolescents, Children, and Toddlers in India and Healthy Adolescents and Children in the Republic of South Africa","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2019-12-30","conditions":"Meningococcal Immunization, Healthy Volunteers","enrollment":1328},{"nctId":"NCT03917654","phase":"PHASE2","title":"Pfs230D1M-EPA/AS01 Vaccine, a Transmission Blocking Vaccine Against Plasmodium Falciparum, in an Age De-Escalation Trial of Children and a Family Compound Trial in Mali","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-04-24","conditions":"Malaria","enrollment":1301},{"nctId":"NCT03537508","phase":"PHASE3","title":"Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-04-25","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":2627},{"nctId":"NCT03691610","phase":"PHASE3","title":"Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-10-04","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":950},{"nctId":"NCT05252715","phase":"PHASE3","title":"Immunogenicity and Safety of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Volunteers Aged From 3 to 5 Months","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd","startDate":"2021-12-18","conditions":"Meningitis, Meningococcal","enrollment":1200},{"nctId":"NCT06314659","phase":"PHASE3","title":"Immunogenicity and Safety of Group A and C Meningococcal Polysaccharide Conjugate Vaccine in Volunteers Aged 3-5 Months","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd","startDate":"2021-09-17","conditions":"Healthy Population","enrollment":630},{"nctId":"NCT06314685","phase":"PHASE3","title":"Immunogenicity and Safety of MCV4 in Volunteers Aged 6 Months-5 Years","status":"UNKNOWN","sponsor":"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd","startDate":"2021-12-10","conditions":"Healthy Population","enrollment":2450},{"nctId":"NCT06337071","phase":"PHASE2","title":"A Study of the ACYW135 Meningococcal Polysaccharide Conjugate Vaccine","status":"NOT_YET_RECRUITING","sponsor":"Aimei Vacin BioPharm (Zhejiang) Co., Ltd.","startDate":"2024-03-20","conditions":"Meningococcal Meningitis","enrollment":1200},{"nctId":"NCT03673462","phase":"PHASE3","title":"Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-09-17","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":2797},{"nctId":"NCT06165276","phase":"PHASE1","title":"A Phase I, Randomized, Modified Single-blind, Active-controlled (Infants Only), Four-stage, Step-down, Comparative, Multi-center Study","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2006-07-25","conditions":"Meningococcal Immunization","enrollment":285},{"nctId":"NCT03632720","phase":"PHASE3","title":"Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine in Infants and Toddlers When Administered Concomitantly With Routine Pediatric Vaccines in the United Kingdom","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-10-10","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":788},{"nctId":"NCT03630705","phase":"PHASE3","title":"Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the Russian Federation and Mexico","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-10-17","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":525},{"nctId":"NCT04450498","phase":"PHASE4","title":"A Study to Demonstrate Non-inferior Immunogenicity of Yuxi Walvax MPV ACYW® Vaccine in Healthy Subjects Aged 2-10 Years","status":"COMPLETED","sponsor":"Walvax Biotechnology Co., Ltd.","startDate":"2020-12-23","conditions":"Neisseria Meningitides Meningitis","enrollment":260},{"nctId":"NCT05298644","phase":"PHASE2, PHASE3","title":"COVID-19 Paediatric VLA2001-321 Study","status":"WITHDRAWN","sponsor":"Valneva Austria GmbH","startDate":"2022-10-01","conditions":"SARS-CoV-2 Infection","enrollment":""},{"nctId":"NCT03636906","phase":"PHASE1, PHASE2","title":"Respiratory Syncytial Virus (RSV) Investigational Vaccine in Infants Aged 6 and 7 Months Likely to be Unexposed to RSV","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2019-04-08","conditions":"Respiratory Syncytial Virus Infections","enrollment":201},{"nctId":"NCT02699840","phase":"","title":"Observational Safety Study of Menactra® Administered Under Standard Health Care Practice in the Russian Federation","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2016-02","conditions":"Meningitis, Meningococcal Meningitis, Meningococcal Infections","enrollment":100},{"nctId":"NCT02864927","phase":"PHASE4","title":"Postmarketing Surveillance Study for Use of Menactra® in the Republic of Korea","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2016-07-21","conditions":"Meningitis, Meningococcal Meningitis, Meningococcal Infections","enrollment":1311},{"nctId":"NCT01890759","phase":"PHASE3","title":"Immunogenicity and Safety of Menactra® Vaccine in Subjects Aged 9 to 23 Months in India and in the Russian Federation","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2013-06-25","conditions":"Meningitis, Meningococcal Infection","enrollment":300},{"nctId":"NCT03476135","phase":"PHASE3","title":"Immunogenicity and Safety of a Booster Dose of a Quadrivalent Meningococcal Conjugate Vaccine in Children","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-02-27","conditions":"Meningococcal Infections","enrollment":91},{"nctId":"NCT02842866","phase":"PHASE3","title":"Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adults 56 Years and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2016-07-15","conditions":"Meningitis, Meningococcal Meningitis, Meningococcal Infections","enrollment":907},{"nctId":"NCT02955797","phase":"PHASE3","title":"Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2017-02-24","conditions":"Meningitis, Meningococcal Meningitis, Meningococcal Infections","enrollment":918},{"nctId":"NCT03205371","phase":"PHASE3","title":"Immunogenicity and Safety of a Meningococcal Conjugate Vaccine Given Concomitantly With Other Vaccines in Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2016-11-07","conditions":"Meningitis, Meningococcal","enrollment":1183},{"nctId":"NCT00875524","phase":"PHASE2","title":"Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Subjects","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2009-03","conditions":"Dengue Virus, Dengue Fever, Dengue Hemorrhagic Fever","enrollment":180},{"nctId":"NCT02752906","phase":"PHASE3","title":"Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate Vaccine","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2016-04-15","conditions":"Meningitis, Meningococcal Meningitis, Meningococcal Infections","enrollment":810},{"nctId":"NCT02842853","phase":"PHASE3","title":"Immune Lot Consistency, Immunogenicity, and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2016-07-15","conditions":"Meningitis, Meningococcal Meningitis, Meningococcal Infections","enrollment":3344},{"nctId":"NCT01732627","phase":"PHASE2","title":"Study of a Quadrivalent Meningococcal Conjugate Vaccine in Subjects Aged 56 and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2012-11-12","conditions":"Meningitis, Meningococcal Meningitis, Meningococcal Infections","enrollment":301},{"nctId":"NCT02199691","phase":"PHASE2","title":"Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2014-07-22","conditions":"Meningitis, Meningococcal Meningitis, Meningococcal Infections","enrollment":1715},{"nctId":"NCT03205358","phase":"PHASE2","title":"Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2015-03-31","conditions":"Meningitis, Meningococcal Meningitis, Meningococcal Infections","enrollment":188},{"nctId":"NCT01049035","phase":"PHASE2","title":"A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2009-12-16","conditions":"Meningitis, Meningococcal Infection","enrollment":580},{"nctId":"NCT03077438","phase":"PHASE3","title":"Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Children Aged 2 to 9 Years","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2017-02-17","conditions":"Meningitis, Meningococcal Meningitis, Meningococcal Infections","enrollment":1000},{"nctId":"NCT05229536","phase":"PHASE2","title":"Immunogenicity and Safety of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Volunteers Aged From 3 to 35 Months","status":"COMPLETED","sponsor":"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd","startDate":"2018-12-21","conditions":"Meningitis, Meningococcal","enrollment":720},{"nctId":"NCT00459316","phase":"PHASE1, PHASE2","title":"Safety of and Immune Response to a Meningitis Vaccine in HIV-Infected Children and Youth","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2007-06","conditions":"HIV Infections, Meningitis","enrollment":384},{"nctId":"NCT04358731","phase":"PHASE2, PHASE3","title":"Study to Evaluate the Lot to Lot Consistency of SIIPL Meningococcal ACYWX Conjugate Vaccine and to Compare Its Safety and Immunogenicity With That of Licensed Meningococcal ACWY Vaccine Menactra® in Healthy Individuals 18-85 Years of Age","status":"COMPLETED","sponsor":"Serum Institute of India Pvt. Ltd.","startDate":"2019-12-27","conditions":"Vaccine for Meningococcal Disease","enrollment":1640},{"nctId":"NCT04204096","phase":"PHASE3","title":"Immune Equivalence Between Multi-dose and Single Dose Formulation of Vi-DT and Their Overall Safety (Phase III)","status":"COMPLETED","sponsor":"International Vaccine Institute","startDate":"2020-02-04","conditions":"Typhoid","enrollment":1800},{"nctId":"NCT03964012","phase":"PHASE3","title":"Study to Assess Immunegnicity & Safety of Pentavalent Meningococcal Vaccine (NmCV-5)","status":"COMPLETED","sponsor":"Serum Institute of India Pvt. Ltd.","startDate":"2019-08-20","conditions":"Meningococcal Meningitis","enrollment":1800},{"nctId":"NCT02810340","phase":"PHASE1","title":"Study of Meninigococcal Conjugate Vaccine Containing Serogroups A,C,Y,W and X (MCV5) in Healthy Adults","status":"COMPLETED","sponsor":"PATH","startDate":"2016-08-01","conditions":"Meningococcal Vaccines","enrollment":60},{"nctId":"NCT04689191","phase":"PHASE3","title":"A Phase III Clinical Trial of the Group A and C Meningococcal Polysaccharide Vaccine","status":"UNKNOWN","sponsor":"Wei Cun","startDate":"2020-09-15","conditions":"Meningitis, Meningococcal","enrollment":1280},{"nctId":"NCT00136604","phase":"PHASE3","title":"Response to GSK Biologicals' Tritanrix-HepB/Hib-MenAC Vacc (4th Dose) at 15-24m & Mencevax ACWY at 24-30m","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-01-22","conditions":"Whole Cell Pertussis, Haemophilus Influenzae Type b, Hepatitis B","enrollment":617},{"nctId":"NCT01430689","phase":"PHASE4","title":"Maternal Flu Vaccine Trial in Bamako, Mali","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2011-09-12","conditions":"Influenza","enrollment":4193},{"nctId":"NCT01934140","phase":"PHASE3","title":"Study to Evaluate the Long-term Antibody Persistence of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine (GSK134612) Versus Mencevax ACWY in Healthy Adolescents and Adults and Booster Response to MenACWY-TT Vaccine Administered at 10 Years Post-primary Vaccination","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-04","conditions":"Infections, Meningococcal","enrollment":311},{"nctId":"NCT01553279","phase":"PHASE3","title":"Immunogenicity and Safety of V419 (PR51) in Combination With MCC in Infants and Toddlers (V419-011)","status":"COMPLETED","sponsor":"MCM Vaccines B.V.","startDate":"2012-03-30","conditions":"Neisseria Meningitidis, Bacterial Infections, Virus Diseases","enrollment":284},{"nctId":"NCT01839188","phase":"PHASE3","title":"Spanish Mixed HEXA/PENTA/HEXA Schedule (V419-010)","status":"COMPLETED","sponsor":"MCM Vaccines B.V.","startDate":"2013-05-01","conditions":"Neisseria Meningitidis, Bacterial Infections, Virus Diseases","enrollment":385},{"nctId":"NCT02858570","phase":"PHASE2, PHASE3","title":"Conjugate Vaccine Against Meningococcus C a Brazilian Project","status":"UNKNOWN","sponsor":"The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)","startDate":"2018-09-25","conditions":"Serogroup C Meningococcal Meningitis","enrollment":1644},{"nctId":"NCT00127855","phase":"PHASE2","title":"Dose Ranging Study of Combined Haemophilus Influenzae Type B-Meningococcal Serogroups CY (Hib-MenCY-TT) Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-03-01","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis","enrollment":409},{"nctId":"NCT00129129","phase":"PHASE2","title":"Comparison of GSKBiologicals' Hib-MenCY-TT Vaccine vs Licensed Hib Conjugate or Meningococcal Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-08-01","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis","enrollment":756},{"nctId":"NCT00289783","phase":"PHASE3","title":"Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-02-22","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis","enrollment":4441},{"nctId":"NCT00282295","phase":"PHASE4","title":"US-licensed Combined Vaccine Against Tetanus & Diphtheria, Given With US-licensed Vaccine Against Meningococcal Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-01-25","conditions":"Acellular Pertussis, Tetanus, Diphtheria","enrollment":1344},{"nctId":"NCT00134719","phase":"PHASE2","title":"Hib-MenCY-TT Vaccine Study Compared to Licensed Hib and Meningococcal Serogroup C Conjugate Vaccines","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-04-11","conditions":"Neisseria Meningitidis, Haemophilus Influenzae Type b","enrollment":1104},{"nctId":"NCT01867463","phase":"PHASE1","title":"Testing Pfs25-EPA/Alhydrogel as a Potential Malaria Transmission Blocking Vaccine","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2013-03-27","conditions":"Malaria","enrollment":230},{"nctId":"NCT00443846","phase":"PHASE3","title":"RotaTeq® and Meningococcus C Vaccine in Healthy Infants (V260-016)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-02-13","conditions":"Meningitis, Meningococcal, Rotavirus Infections","enrollment":247},{"nctId":"NCT00290329","phase":"PHASE4","title":"Safety of Purified Meningococcal Vaccine With Serogroups ACWY, in 3,000 Filipino Subjects Aged > 2 Years","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-01-14","conditions":"Infections, Meningococcal","enrollment":249},{"nctId":"NCT00871338","phase":"PHASE2","title":"Study to Evaluate GSK Biologicals' GSK2197870A Vaccine Given as Primary Course in Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-06-24","conditions":"Neisseria Meningitidis, Haemophilus Influenzae Type b","enrollment":284},{"nctId":"NCT03263403","phase":"PHASE2, PHASE3","title":"Non Inferiority Trial of Locally Manufactured Meningococcal ACWY Vaccine 'Ingovax ACWY' in Bangladesh.","status":"COMPLETED","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2017-08-21","conditions":"Meningococcal Vaccine","enrollment":88},{"nctId":"NCT00631995","phase":"PHASE1","title":"Safety and Immunogenicity of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2008-04","conditions":"Meningitis, Meningococcal Infection","enrollment":360},{"nctId":"NCT02640404","phase":"PHASE2","title":"Safety of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine in Healthy Subjects in Vietnam","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2016-06-06","conditions":"Meningitis, Meningococcal Meningitis, Meningococcal Infections","enrollment":224},{"nctId":"NCT02591290","phase":"PHASE4","title":"Immunogenicity and Safety of Two-Dose Series of Menactra® in Japanese Healthy Adult Subjects","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2015-10-20","conditions":"Meningitis, Meningococcal Meningitis, Meningococcal Infections","enrollment":60},{"nctId":"NCT01839175","phase":"PHASE3","title":"Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunisation Followed by Booster Vaccination","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2013-04","conditions":"Neisseria Meningitidis, Bacterial Infections, Virus Diseases","enrollment":350},{"nctId":"NCT00345579","phase":"PHASE3","title":"Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 2, 4, 6 and 12 to 15 Months of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-09","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis","enrollment":4432},{"nctId":"NCT01593514","phase":"PHASE4","title":"Understanding the Immune Response to Two Different Meningitis Vaccines","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2012-12","conditions":"Meningitis, Meningococcal Disease, Septicaemia","enrollment":20},{"nctId":"NCT00345683","phase":"PHASE3","title":"Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 12 to 15 Months of Age.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-07","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis","enrollment":4021},{"nctId":"NCT02633787","phase":"PHASE4","title":"Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra® Approximately 4 Years Earlier","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2015-12","conditions":"Meningitis, Meningococcal Meningitis, Meningococcal Infections","enrollment":110},{"nctId":"NCT02878291","phase":"PHASE1","title":"Safety Study of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Healthy Volunteers Aged Above 3 Months","status":"UNKNOWN","sponsor":"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd","startDate":"2016-06","conditions":"Meningitis, Meningococcal","enrollment":200},{"nctId":"NCT01359449","phase":"PHASE3","title":"Study of Two Doses of Menactra® or One Dose of Monovalent Meningococcal Group C Vaccine With Routine Immunizations","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2011-05","conditions":"Meningitis, Meningococcal Infection","enrollment":123},{"nctId":"NCT00483574","phase":"PHASE3","title":"Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2007-05","conditions":"Meningococcal Meningitis, Measles, Mumps","enrollment":1378},{"nctId":"NCT01339923","phase":"PHASE3","title":"A Phase 3B, Open Label, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Alone to Healthy Infants According to Different Immunization Schedules and to Healthy Children Aged 2 to 10 Years","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2011-04","conditions":"Meningococcal Disease, Meningococcal Meningitis","enrollment":1409},{"nctId":"NCT00254995","phase":"","title":"Descriptive, Post-marketing, Surveillance Safety Study of Menactra Vaccine","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2005-07","conditions":"Meningitis, Meningococcal Disease","enrollment":62626},{"nctId":"NCT00539032","phase":"PHASE3","title":"Immunology and Safety of Menactra® in Children in Saudi Arabia","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2007-09","conditions":"Meningitis, Meningococcemia","enrollment":238},{"nctId":"NCT00700635","phase":"PHASE2","title":"Dose Comparison Study of Menactra® in US Children","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2008-06","conditions":"Meningitis, Meningococcal Infection, Neisseria Meningitidis","enrollment":333},{"nctId":"NCT00771849","phase":"PHASE2","title":"Study of Antibody Responses After a Dose of Tetravalent Meningococcal Diphtheria Conjugate Vaccine in Children","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2003-08","conditions":"Meningitis, Meningococcemia","enrollment":103},{"nctId":"NCT00269477","phase":"PHASE2","title":"Persistence of Antibodies in Adolescents and Adults 15 to 23 Years Who Received One Dose of Menactra® or Menomune®","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2005-12","conditions":"Meningitis, Meningococcal Infection","enrollment":145},{"nctId":"NCT00384397","phase":"PHASE3","title":"A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2006-09","conditions":"Meningococcal Meningitis, Measles, Mumps","enrollment":1128},{"nctId":"NCT00850603","phase":"PHASE4","title":"Safety and Immunogenicity of Intradermal Versus Subcutaneous Doses of Menomune®","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2002-10","conditions":"Meningococcal Infections, Meningitis","enrollment":170},{"nctId":"NCT00422292","phase":"PHASE3","title":"Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2006-12","conditions":"Meningococcal Meningitis, Measles, Mumps","enrollment":1664},{"nctId":"NCT02500511","phase":"","title":"Persistence of Protective Antibody Titers 12-24 Months After NmVac4-A/C/Y/W-135-DT Vaccination: Follow Up Study","status":"COMPLETED","sponsor":"JN-International Medical Corporation","startDate":"2015-06","conditions":"Meningococcal Meningitis, Meningococcal Infections","enrollment":50},{"nctId":"NCT00700713","phase":"PHASE2","title":"Antibody Persistence and Booster Dose Response in Subjects Who Received Menactra® Three Years Earlier in Study MTA26","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2008-06","conditions":"Meningitis, Meningococcemia","enrollment":181},{"nctId":"NCT01659996","phase":"PHASE4","title":"Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2012-07","conditions":"Meningitis, Meningococcal Infection, Diphtheria","enrollment":1394},{"nctId":"NCT02003495","phase":"PHASE3","title":"Immunogenicity and Safety of Meningococcal (A, C, Y and W135) Conjugate Vaccine","status":"COMPLETED","sponsor":"Beijing Minhai Biotechnology Co., Ltd","startDate":"2013-10","conditions":"Meningitis","enrollment":2195},{"nctId":"NCT02003313","phase":"PHASE3","title":"Immunogenicity and Safety of Group A, C, Y and W135 Meningococcal Polysaccharide Vaccine","status":"COMPLETED","sponsor":"Beijing Minhai Biotechnology Co., Ltd","startDate":"2013-11","conditions":"Meningitis","enrollment":1260},{"nctId":"NCT00444951","phase":"PHASE3","title":"Immunogenicity and Safety of Menactra® Vaccine in Adolescents in Saudi Arabia","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2007-02","conditions":"Neisseria Meningitidis, Meningococcal Infections","enrollment":450}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":11,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Lanzhou Institute"],"phase":"phase_3","status":"active","brandName":"A+C Meningococcal Polysaccharide Vaccine","genericName":"A+C Meningococcal Polysaccharide Vaccine","companyName":"Hualan Biological Engineering, Inc.","companyId":"hualan-biological-engineering-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"This vaccine stimulates the immune system to produce antibodies against meningococcal serogroups A and C polysaccharide antigens, providing protection against meningococcal disease. Used for Prevention of meningococcal disease caused by Neisseria meningitidis serogroups A and C.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}